Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
130
Trial Sponsor
Clinical Trial Start Date
November 3, 2020
0Primary Completion Date
January 1, 2030
0Study Completion Date
January 1, 2030
0Clinical Trial Study Type
Observational0
Intervention Type
Biological0
Intervention Name
SB-FIX0
SB-9130
SB-3180
Observational Clinical Trial Type
Case-Only0
Observational Study Perspective
Prospective0
Participating Facility
Official Name
Long-Term Follow-up of Subjects Who Were Treated With SB-318, SB-913, or SB-FIX, for Targeted Genome Editing Into the Albumin Gene in the Liver0
Last Updated
September 26, 2023
0Study summary
Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
